SVA SINOVAC BIOTECH LTD
Research report · from SEC EDGAR
executive summary
SINOVAC BIOTECH LTD (SVA). Revenue is $386.0M (+6.8% y/y) at a -52% net margin. It is not yet profitable. Our health score is C (62/100). No major red flags on file. It funds itself; low dilution risk.
Revenue (FY)
$386.0M
+6.8% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 0
Cash & ST investments
$5.97B
Operating cash flow
-$512.2M
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated today by stocktools.ai.